麥美華—快速診斷技術與試劑的研發和生產銷售商今日宣布：通過與泰普生物的戰略合作以實現在中國的快速發展。泰普生物是中國診斷（試劑）領域的主要的企業之一。
去年有著近3000萬美金銷售成績的泰普已經建立了良好的醫療客戶基礎，擁有了29個省市的2000多家醫院和醫療診斷機構。泰普的產品涵蓋了45種分子診斷產品，包括（在這個領域的）一些高端品牌。泰普同樣擁有許多的專家、學者，博士，通過中國的病理學委員會工作于整個中國的的研究院和醫院中。
“這種戰略合作能帶來強大的銷售和泰普已經建立好的強大的市場平臺，通過與麥美華世界水準的產品合作，提供給客戶高質量的診斷方式，對合作雙方來說互利互惠的。”麥美華董事長陳錦華說，“對我們而言，中國是一個長期的需要主動開拓的市場，和泰普的合作是我們開拓中國市場的必然選擇。”
麥美華與泰普最初的合作方式是通過泰普的銷售渠道來增加我們在中國的產品銷售。在上個月，泰普將麥美華的快速檢測試劑進行了預售前的客戶測試，取得了良好的反饋。除此之外，泰普還將它們送往中國醫療疾病診斷與預防（CDC）中心進行檢測。
陳董事長說：“我們相信通過與泰普的戰略合作，將來會發展為共同研發快速診斷試劑，技術轉讓，以及共同合作研發新項目上來。如今的中國市場不斷變化，新的醫療體系將會形成，麥美華和泰普將共同致力于技術優化和產品成本優化。”
2009年4月，中國政府在國家醫療體系改革上投入了1250億美元，主要用于建立基礎醫療設施，普及城市和農村的公共醫療服務，為全體居民提供基礎醫療和藥物計劃，以及進行公共醫療體系的重建。
“我們很高興能和麥美華合作，共同開發中國市場，同時（可以）為我們的顧客提供最新的診斷方式。如今的診斷領域不斷變化，泰普與麥美華合作可以及時響應市場需求”泰普董事長姚銘鋒說，“我們與麥美華的長期戰略合作將靈活地根據市場需求研發及將研發成果商業化。”
除了醫療產品的銷售和物流配送外，泰普還計劃建立自己獨立的醫療診斷中心，用來為客戶提供方便快捷的診斷服務。泰普已經考察了許多的城市和地區來建立臨檢中心，直接提供自己的醫療產品和醫學專家服務。
原文:
MedMira Enters Strategic Partnership with Triplex International Biosciences to Accelerate Growth in China
Halifax, Nova Scotia June 30, 2009 - MedMira Inc., (“MedMira”) (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that it is making progress on market development in China through the creation of a strategic partnership with Triplex International Biosciences Co., Ltd. (Triplex), a major player in China’s diagnostics sector.
With recorded sales revenue of nearly USD $30 million last year, Triplex has a well established healthcare customer base, which includes over 2,000 hospitals and medical institutions across 29 provinces and autonomous regions within China. The Triplex product line is comprised of over 45 molecular pathology diagnostics products, including some of the top brands in the industry. Triplex also has access to many experts, academics and doctors working in hospitals and research institutions across China through the Chinese Committee of Pathology.
“This partnership brings the strong sales and marketing platform that Triplex has built in China together with MedMira’s world-class products, to offer customers quality diagnostic solutions and increase revenue potential for both companies,” said Hermes Chan, CEO of MedMira Inc. “For us China is a long-term business initiative and working with Triplex is a natural extension of MedMira’s growth strategy for the China market.”
MedMira will initially be working with Triplex to increase product sales in China through their existing distribution channels. Over the course of the last few months, Triplex has undertaken market testing with MedMira rapid tests and the feedback has been very positive. In addition to these pre-sales customer trials, Triplex also engaged the China Centers for Disease Control and Prevention (CDC) to evaluate the MedMira tests.
Chan continued, ”We believe our partnership with Triplex will evolve to include co-development of new rapid tests, technology transfers, and collaborative research projects in the future. Market conditions are changing rapidly in the China as new healthcare system reforms take shape. Together MedMira and Triplex can capitalize on the need for improved and cost-effective diagnostics.”
In April 2009, China’s government announced a $125 billion USD investment in significant reforms to their country’s healthcare system. Major initiatives include the establishment of basic medical services for all urban and rural residents, universal access to public health services, a basic medical and drug plan for all residents, and the reorganization of the public hospital system.
“We are pleased to work with MedMira in expanding their access to the China market and offer our customers new rapid diagnostic solutions. The diagnostics sector and overall healthcare market here in China is rapidly changing and together Triplex and MedMira can respond to market demand for better, faster diagnostics,” said Yiu Ming Fung, President and Chairman of Triplex. “Our long-term growth strategies are in line with MedMira’s and our partnership enables the flexibility to develop and commercialize new rapid tests to meet market demand.”
In addition to sales and distribution of diagnostic products, Triplex intends to operate independent diagnostic centres to provide fast and convenient medical testing services. Triplex has identified a number of cities and regions to set up its diagnostic centers where they will serve the community directly using Triplex’s wide range of diagnostic products and technical expertise.
About Triplex International Biosciences Co., Ltd.
Triplex is one of the leading molecular pathology diagnostic companies in China and its line of diagnostic solutions is one of the tope brands in the industry. Over the past five years, Triplex has grown from seven people to a team of 170 supporting the Company’s annual sales growth rate of 400 percent. Triplex sells more than 45 products to over 2000 hospitals and medical institutions across 29 provinces and cities in China. The Company has also developed more than 30 diagnostic products through its Engineering Laboratory for Molecular Diagnostic Technology in Fuzhou, three R&D centers, and five joint R&D bases with Peking University Medical School, the Fourth Military Medical University in Xi-an, Sichuan University, Fujian Medical University, as well as CAS Shanghai Life Sciences Research Institute. To learn more about Triplex visit m.gjeo.cn.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal?, MiraWell?, MiraCare? and Multiplo? brands in global markets. MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
